



   
Solid Tumour Section 
Review 
 
Atlas Genet Cytogenet Oncol Haematol. 2013; 17(3)  221 
INIST-CNRS 
 
OPEN ACCESS JOURNAL 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
Head and neck: Thymus: Thymoma: an overview 
Marius Raica, Domenico Ribatti 
"Victor Babes" University of Medicine and Pharmacy, Department of Morphologic Microscopy, 
Angiogenesis Research Center Timisoara, Timisoara, Romania (MR), University of Bari, Department of 
Basic Medical Sciences, Neurosciences and Sensory Organs, Bari, Italy (DR) 
 
Published in Atlas Database: October 2012 
Online updated version : http://AtlasGeneticsOncology.org/Tumors/ThymomaID5403.html 
DOI: 10.4267/2042/48767 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 





Thymoma is the most frequent primary tumor of the 
anterior and superior mediastinum with an incidence 
that ranges between 0.2 and 1.5% from all malignant 
tumors (Schmidt-Wolf et al., 2003; Koppitz et al., 
2012). Usually, it occurs in adults over 40 years and is 
asymptomatic for long time. When the thymoma 
becomes invasive, it becomes clinically evident by 
compression signs or/and respiratory symptoms. 
Almost half of the cases are detected by routine 
thoracic X-ray examination and the majority has 
between 5 and 10 cm in their larger diameter. However, 
any imagining criterion is specific for the diagnosis of 
thymoma (Strollo et al., 1997). 
The term "thymoma" is restricted to the tumor of the 
thymus that consists of epithelial cells, independently 
from the presence and number of lymphocytes. Almost 
all thymomas occur in the anterior and superior 
mediastinum of the adult, and occasionally, with oter 
locations (latero-cervical, in the thyroid, in the ilus of 
the lung). Typical thymoma is a solid, yellow-grayish 
and lobulated tumor. In approximately 80% of cases 
the tumor is encapsulated, and when it is large show  
many foci of cystic degeneration. Even apparently 
encapsulated, the rate of recurrences is about 15%.
Many "malignant" thymomas have a slow rate of 
proliferation, and the recurrence is noticed in 2% of the 
encapsulated and in 20 to 40% of the invasive 
thymomas. Thymoma is frequently associated with 
immune-mediated systemic diseases, like 
neuromuscular syndroms (myasthenia gravis, Lambert-
Eaton syndrome, myositis), hypogammaglobulinemia 
(12%), hematologic diseases (erythroid hypoplasia, 
erythrocytosis, leukemia), collagen diseases 
(scleroderma, Sjögren syndrome) or autoimmune 
endocrine diseases (Boonen et al., 2000).  
Epidemiological data showed that in patients with 
thymoma the incidence of synchronous malignant 
tumors is higher than in other groups and it was 
reported in 28% of the cases in a series of 128 patients 
with thymoma (Welsh et al., 2000). 
Myasthenia gravis and thymoma 
In patients with myasthenia gravis the thymus shows a 
marked lymphoid follicle hyperplasia, as unique 
morphologic abnormality in 65% of cases. In 10% of 
patients myasthenia gravis is associated with thymoma 
(with or without follicular hyperplasia) and there are 
not found abnormalities in the other 25% of cases. This
relation is also supported by the fact that 30 to 45% of 
patients with thymoma develop clinically evident 
myasthenia gravis (Raica et al., 1999). Until now, there 
were not demonstrated ultrastructural or 
immunohistochemical differences between thymomas 
with and without myasthenia gravis. Recent studies on 
large series were not able to demonstrate that 
myasthenia is a prognostic element for the behavior of 
thymoma. In all cases, myasthenia gravis is associated 
with a defect of the nicotinic receptor for acetylcholine 
(AchR). A similar (or even identical) protein was 
identified in the normal human thymus. This protein is 
located in a subset of thymic cells that have similar 
immunophenotype as striated muscle cells (myoglobin 
and desmin positive), called myoid cells. In the non-
neoplastic thymus of patients with myasthenia gravis 
were identified aggregates of myoid cells, infiltrating 
the stroma. T cells activate AchR reactive B 
lymphocytes. Therefore, the process begins in the 
thymus and than continues in the entire immune system 
by autoantibodies production. Surgical treatment is 
more efficient if the thymus has follicular hyperplasia, 
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Thymoma: general features 
The large majority of thymomas consist of a mixture of 
neoplastic epithelial cells and non-neoplastic 
lymphocytes. The rate between these two cell 
populations is variable from a case to another, or even 
in different areas of the same tumor. Neoplastic 
epithelial cells may be polygonal, round, oval, and 
stellate or spindle in shape. Nuclei have a fine granular 
chromatin, smooth outline, and nucleolus is often 
prominent (especially in round and polygonal shaped 
cells). Thymomas with epithelial predominance contain 
prominent perivascular spaces with lymphocytes, 
proteinaceous fluid, red blood cells, and foamy 
macrophages. More rare are found rosette-like (without 
evident lumen) or glandular-like aspects or even 
abortive Hassall corpuscles. The presence of rosettes 
with well-defined lumen does not correlate with the 
diagnosis of thymoma, and usually is a character of a
carcinoid tumor of the thymus. In some cases may be 
noticed micro-cystic, tubular and pseudo-papillary 
zones. In lymphocyte-rich thymoma areas with 
medullary differentiation are frequently noticed. The 
capsule of the tumor is thick, fibrous, and often 
calcified. It gives rise to fibrous septa that form 
angulated lobules into the parenchyma of the tumor. It 
is thought that extensive fibrosis in some cases is the 
result of spontaneous tumor regression, but there ar  no 
proofs to support this hypothesis. 
Ultrastructurally, neoplastic epithelial cells contai  
branched tonofilaments, form desmosomes, and have 
long cytoplasmic processes and a distinct basal lamina. 
Epithelial cells are arranged in sheets and cords that 
contain lymphocytes, and the aspect is mimicry of the 
medulla of the normal thymus. These characters are 
useful to differentiate thymoma from other tumors of 
the mediastinum (carcinoid, malignant lymphoma, 
germ cell tumor or solitary fibrous tumor). The 
presence of epithelial cells on ultrastructural 
examination does not necessary mean thymoma. We 
must be aware especially on malignant lymphoma that 
included islands of normal thymus. 
The tumor microenvironment was significantly less 
investigated than neoplastic cells of thymoma. In part, 
tumor progression may be stimulated of inhibited by 
changes in the tumor stroma, and it was found a 
significant increase in the number and spatial 
distribution of mast cells and high values for immature 
and intermediate blood vessels, which are 
characteristics of tumor-associated angiogenesis (Raica 





Classification of thymoma 
Classification of thymoma is one of the most elusive in 
pathology, based on one hand on the reduced number 
of cases and on the difficulty to interpret histological 
findings on the other. The majority of the tumors of the 
thymus are thymomas and the term is restricted to the 
epithelial proliferations of the thymic stroma. 
The present classification of thymoma includes the typ  
A ("A", atrophic), type B ("B", bioactive), and C ("C", 
carcinoma). 
Over the years, there were proposed many systems, but 
only two or three remained in use. Perhaps the most 
simple, but at the same time, the most subjective, is the 
classification proposed by Lattes and Bernatz that take 
into account the predominant cell type, as follows: 
spindle thymoma, thymoma with lymphocyte 
predominance (over 66% lymphocytes), with epithelial 
predominance (over 66% epithelial cells), and 
predominantly mix (epithelial cells between 34 and 
66%). Examination is extremely subjective, because 
there are estimated two different cell types, as 
demonstrated by immunohistochemistry. Moreover, 
this classification brings nothing in the field of 
prognosis. 
In last years, the classification proposed by Muller-
Hermelink had a strong impact, because it is 
histogenetic and correlates with prognosis. The major 
criticism is related to the "well differentiated thymic 
carcinoma", included in the group of thymoma by all 
other publications (Rosai, 1999; Suster and Moran, 
1999; Kuo, 2001).  
This is the reason why many pathologists prefer the 
classification proposed by Juan Rosai (Rosai, 1999). 
Malignancy of thymoma is defined in terms of natural 
evolution.  
Completely encapsulated thymomas were considered to 
be benign, and invasive thymomas were considered 
malignant. On this basis, Masaoka (1981) introduced 
the "clinical" classification that found many adepts: I - 
encapsulated at macroscopy, without microscopic 
invasion; II1 - macroscopic invasion in the adipose 
tissue or pleura; II2 - microscopic invasion of the 
capsule; III - macroscopic invasion in surrounding 
organs; IVa - pleural or pericardial spread; IVb - distant 
metastasis. With few changes, this classification was 
incorporated in the TNM system, proposed by 
Yamakawa. 
The grade of thymoma is another unsolved problem 
and a permanent subject of dispute. It was shown that 
thymoma without overt cytological atypia have better 
prognosis (Yoneda et al., 2000), but exceptions from 
this rule were also reported. The grading system large y 
accepted now is in fact a compromise: we have not a 
better one! Therefore, the grade was in part overlapped 
on the pathologic diagnosis. Actually, the histologic 
grade of thymoma in its present form has any impact on 
prognosis or therapy. 
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Figure 1. Histological types of thymoma. Type A (A, H&E staining, x400). Type AB (B, Masson staining, x400). Type B1 (C, Masson 
staining, x400). Type B2 (D, H&E staining, x400). Type B3 (E, Masson staining, x400). Thymic carcinoma (F, H&E staining, x100). 
 
Clinics and pathology 
Pathology 
Pathologic diagnosis 
- Thymoma type A (spindle cell, medullary) consists 
of cells that are spindle or oval in shape, without atypia, 
and lymphocytes are rare or even absent. The pattern of 
proliferation is focally storiform, and may contain 
rosette-like structures  
and pseudo-glands close to the capsule. Hassall's 
corpuscles are rarely found. Nuclei of tumor cells have  
fine granular chromatin with small nucleoli. Not all 
cells are spindles in shape. Some of them may be oval 
and form the large majority of the cell population. 
More than 95% of thymoma type A are encapsulated, 
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but some of them may invade the capsule, or vary rare,
the lung. Exceptionally were reported cases with such a 
thymoma with atypical cells, mitotic activity and 
necrosis. It is often difficult to classify such a c se: 
undifferentiated thymoma type A? Spindle cell variant 
of thymoma type B3? Or sarcomatoid carcinoma? Until 
now, there are no data to help us. The presence of a 
reticular fiber network around individual cells and its 
absence around perivascular spaces would be in the 
favor of thymoma type A, but this observation was not 
enough investigated to be used. There were described 
some "unusual" forms of thymoma type A: with 
pseudo-sarcomatous stroma, haemangiopericytic, with 
rosettes, micronodular, basaloid, with papillar and 
glandular structures. Anyway, we do not know yet what 
means "usual" thymoma type A. 
- Thymoma type AB (mix) is characterized by type A 
areas and lymphocyte-rich areas. Between the two 
different patterns of the tumor may be a clear-cut edge 
or the transition between them is gradual. Frequently, 
type A area is reduced, but it has the same aspects as 
described above. The term "mix" is used to draw 
attention on the dual cell population: neoplastic 
epithelial and non-neoplastic lymphocytes. 
- Thymoma type B1 (lymphocyte-rich, lymphocytic, 
cortical) is similar to the normal functional thymus and 
consists of areas that are close in structure with the 
cortex (that predominate) and medulla. Differentiation 
from the normal thymus may be impossible at low 
power magnification. Medullary differentiated areas are 
usually round and may be erroneously interpreted as 
germ center; on occasion, they may contain aggregates 
of epithelial cells or Hassall bodies. Perivascular spaces 
are rarely found and are less prominent than in other 
forms of thymoma. 
- Thymoma type B2 (cortical) consists of isolated or in 
small groups arranged epithelial cells and many 
lymphocytes. Usually, perivascular spaces are 
numerous and large. Occasionally, epithelial cells are 
arranged in palisade around perivascular spaces. Foci 
of medullary differentiation are less evident (with or 
without Hassall corpuscles) or they are absent. 
Epithelial cells are polygonal in shape (thymoma with 
large polygonal cells), more numerous than in 
thymoma type B1, they have nuclei with fine granular 
chromatin, prominent nucleoli, and rich cytoplasm. 
Lymphocytes may be immature, with large nuclei, 
visible cytoplasm and high mitotic activity (Ki67 index 
over 80%). Opposite to thymoma B1, this tumor does 
not recapitulate the differentiation of the normal 
thymus. 
- Thymoma type B3 (epithelial, atypical, well 
differentiated thymic carcinoma) consists of epithel al 
cells that are round or polygonal in shape. Atypical 
elements are mild or absent, but the epithelial 
component proliferates in large sheets and lymphocytes 
are reduced in number. Epithelial cells have small 
nucleoli and mitotic figures are rare. The tumor 
preserves some characters of thymic differentiation: 
lobulation, dual cell population, and perivascular 
spaces. The perivascular arrangement of epithelial cells
and squamous differentiated areas are frequently found. 
This tumor is more frequently invasive than 
"conventional" thymoma, but it may co-exist with 
thymoma B1, B2 or C. 
There were described some unusual variants of 
thymoma with polygonal and round cells: microcystic, 
cystic, cribriform, with clear cells, rich in plasma cells, 
with myoid cells and starry sky. The classification f 
these forms is often based on the expression of 
monoclonal cytokeratin to differentiate them from 
thymic carcinoma with similar features. 
- Pathology of thymoma after the preoperative 
treatment with corticosteroids. Corticosteroids are 
well-known inducers of thymic involution. It was 
noticed that preoperative administration of 
corticosteroids significantly reduces the diameter of the 
tumor. There are few studies on this subject, but data 
are extremely useful for pathologist. There are 
significant microscopic differences between the 
biopsies before and after the treatment with 
corticosteroids. Tateyama et al. (2001) noticed 
reduction of the tumor mass between 5 to 70%, 
depending the dose and length of the treatment. The 
predominance of proliferating epithelial cells may 
change. In some cases the dominant cell population 
becomes spindle in shape, and in others were noticed 
glandular-like or haemangiopericytoma-like structures. 
Atypical cells were rare or absent and many epithelial 
cells had acidophilic cytoplasm and condensed nuclei. 
The number of lymphocytes dramatically decreased, 
some of them showing fragmented nuclei. In tumors 
with massive regression extensive fibrosis, foamy 
macrophages, and necrosis are frequently noticed. 
Perivascular palisade of epithelial cells, cystic 
structures, and bizarre multinucleated giant cells, or 
giant cells with lobulated nucleus may be noticed in 
some cases. In all cases published until now it was
observed the transformation in thymoma with epithelal 
predominance.  
The presence of degenerative lesions does not 
necessary means regression of the tumor. It is thought 
that epithelial cells degeneration is a consequence of 
depletion in immature T lymphocytes.  
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Figure 2. High molecular weight cytokeratin expression in invasive thymoma (A). VEGF overexpression in thymic carcinoma 
(B). Magnification x400. 
 
In these conditions, the knowledge of preoperative 
medication is essential to avoid a possible confusion 
with well-differentiated carcinoma (as defined in 
Marino-Muller-Hermelink classification). 
- Atypical thymoma: a distinct entity? Based on the 
difficulties in the classification of thymoma, Suster and 
Moran (1999) proposed the term "atypical thymoma". 
In this category were included all the cases that 
preserve some organo-typical characters of thymic 
differentiation, but associated with a given grade of cell 
atypia. The cell population is predominant epithelial, 
with the tendency to squamous transformation at the 
level of both architecture and individual tumor cells. 
Frequently, tumor cells are arranged around 
perivascular spaces, mimicking glandular 
differentiation. This lesion is equivalent to the "well 
differentiated thymic carcinoma" from Marino-Muller-
Hermelink classification. Atypical thymoma is more 
frequently invasive than the conventional thymoma and
can be found in association with typical areas of 
thymoma or/and thymic carcinoma. Although the 
existence of this subtype is supported by some data, 
until now atypical thymoma was not included in 
WHO's classification. 
- Thymic carcinoma (former thymoma type C) is a 
rare tumor with poor prognosis in comparison with 
thymoma (Tomita et al., 2002), and is defined as an 
epithelial proliferation whose individual cells show 
clear characters of malignancy. Opposite to 
conventional thymoma, it is not associated with 
myasthenia gravis. The diagnosis is usually by 
exclusion, because there are not clear criteria to 
differentiate this tumor from carcinoma developed in 
other organs. The thymic carcinoma shows no character 
of thymoma (perivascular spaces, abortive Hassall 
bodies, a/o). The only major difference is the positive 
immunoreaction for CD5 in epithelial cells (this 
immunoreaction is negative in typical thymoma and 
non-thymic carcinoma). Lymphocytes may be present, 
even in large number, but always they are mature T (or 
rarely B) in type. The most common form is the 
squamous cell carcinoma (90% of cases), but there 
were reported many other variants: lymphoepithelioma-
like, sarcomatoid, clear cell, basaloid, papillary, and 
anaplastic (Snover et al., 1982; Iezzoni and Nass, 1996; 
Shimosato and Mukai, 1997; Matsuno et al., 1998). The
prognosis of thymic carcinoma largely depends of the 
pathologic variant (better in cornified squamous cell
carcinoma). 
CD70, a member of the TNF family, is expressed by 
many cases with thymic carcinoma and usually is 
negative in thymoma type B3, and therefore, the 
method is useful for the differential diagnosis (Rosai, 
2004). Tumor cells also express Ki67 and p53, but the 
prognostic relevance of these markers is not yet 
clarified. 
Differential diagnosis of thymoma and related tumors 
may represent itself the topic of a review: it includes 
malignant lymphomas, carcinoid, neuroendocrine 
carcinoma, germ cell tumors, stromal tumor, and 
cervical tumors with thymic derivates. Involution of the 
thymus should be also considered, particularly in the
case of small specimens taken by endoscopic 
procedures. In this condition, aggregates of epithelial 
cells can be over-interpreted as thymoma (Raica et al., 
2007). Actually, an extensive immunophenotyping is 
frequently needed. It is important to mention here 
especially cervical tumors with thymic derivate that 
include cervical ectopic thymoma, hamartomatous 
thymoma, spindle epithelial tumor with thymus like 
elements (SETTLE) and carcinoma with thymus like 
elements (CASTLE). 
The ectopic cervical thymoma has a clear preference 
for female, a benign behavior and the same features as 
the mediastinal counterpart. 
Ectopic hamartomatous thymoma occurs mainly in 
males, supraclavicular or suprasternal, and consists of 
spindle shaped cells with mesenchymal aspect. The 
tumor lacks atypical aspects, necrosis and mitotic 
activity. One component of the tumor that may be 
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noticed only focal consists of solid squamous nests, 
anastomosed cords and cysts lined by epithelium. Small 
aggregates of adipose cells are found between 
neoplastic cells. Lymphocytes are scant, but present in 
all cases. Some authors reported a concentration of 
myoid cells, but their significance is unknown. Despite 
such a tumor can rich large diameter, it has not a 
corresponding tumor in the mediastinum and is benign 
(Zhao et al., 2000). 
Spindle epithelial tumor with thymus like elements 
(SETTLE) is rare, occurs in younger and develops 
around the thyroid. It is a biphasic tumor, one 
component is spindle and shows mitotic activity, and 
the other is cystic glandular. The natural evolution s 
slow, and metastasis was reported after years or even
decades. 
Carcinoma with thymus like elements (CASTLE) also 
has the tendency to be present around or even within 
the thyroid. On the basis of conventional pathologic 
diagnosis, it cannot be differentiated from thymic 
carcinoma. Despite local recurrences are frequent, the 
long-term prognosis is good. 
Genes 
The molecular profile of thymoma 
The immunohistochemical profile of epithelial cells is 
wide, and best studied are, of course, cytokeratins. 
They also express the epithelial membrane antigen and 
carcino-embryonic antigen. Many data from the 
literature revealed the value of cytokeratin 
8/cytokeratin 18 and high molecular weight cytokeratin 
for the diagnosis of thymoma (Encica et al., 2004). 
The immunohistochemical expression of cytokeratin is 
heterogeneous, excepting for cytokeratin 19 and high 
molecular weight. On the other hand, cytokeratin 7 is 
positive in many cases, but it stains only few neoplastic 
epithelial cells. This is why it is strongly recommended 
to use a pan-cytokeratin that contains clones 7, 8, 18 
and 19. In such an instance, the immunoreaction is 
intense and homogeneous, excepting for spindle cell 
thymoma. The immunohistochemical method is useful 
not only in the diagnosis, but also in the classification 
of thymoma. The epithelial membrane antigen is 
usually expressed only in pseudo-glandular area. 
Collagen type IV and laminin are found in large 
amount around individual spindle cells. It is well 
known that thymoma-associated lymphocytes are non-
neoplastic, and specific immunophenotyping is not 
necessary. Many T cells have not the characteristic 
profile for mature lymphocytes and express Ki67 
antigen. Thymoma also contains a S100 protein 
positive cell population that consists of interdigitate, 
and with lesser extent, Langerhans cells. Their number 
and distribution correlates with the microscopic variant, 
but their presence is not predictive for invasion. A 
subset of interdigitate cells that co-express CD20 are 
called "asteroid", and their significance is unknow. 
Collagen IV and laminin are found in large amount 
around individual spindle tumor cells but only a slight 
expression of these molecules is noticed in thymoma 
with polygonal or round tumor cells. Somehow strange, 
epithelial cells from thymoma and thymic carcinoma 
express high levels of somatostatin receptor, but on this 
finding is based the scintigraphic detection of 
mediastinal tumors or thymoma recurrence. 
Vascular endothelial growth factor (VEGF) was less 
investigated in the normal thymus and thymoma. The 
immunohistochemical expression of VEGF is strong in 
the prenatal thymus and in the majority of cases with 
thymoma (Cimpean et al., 2008). Virtually, all 
thymomas type B are positive, with the strongest 
intensity in type B3 and thymic carcinoma. In 
experimental model it was shown that gene targeting of 
VEGF-A in thymus epithelium disrupts the blood 
vessel architecture (Muller et al., 2005). Extensive 
studies on large series of patients could support the 
introduction of antiangiogenic therapy in cases with 
aggressive tumors of the thymus. Besides VEGF, other 
growth factors involved in tumor-associated 
angiogenesis were detected in thymoma neoplastic 
cells, like platelet-derived growth factor and its cognate 
receptors (Cimpean et al., 2011). Their clinical 
significance for tumor progression and metastasis of 
thymoma is still uncertain. 
Epidermal growth factor receptor (EGFR) is expressed 
in over 60 to 70% of thymomas (Henley et al., 2002), 
but from these, only half showed correlation with gene 
analysis. EGFR gene mutations were not detected in 
thymoma or thymic carcinoma (Suzuki et al., 2006). 
EGFR immunohistochemical expression did not 
correlate with conventional prognostic factor, but by 
detection by fluorescent in situ hybridization it was 
found a significant correlation with the type, invasion 
and clinical stage. EGFR immunoreactivity was 
associated with more aggressive thymoma types B2 
and B3, but a definite correlation with thymic 
carcinoma was not established (Aisner et al., 2010). 
Based on this data, EGFR expression may be 
considered as an individual prognostic factor and a 
possible target for therapy. 
Other molecular markers were also investigated to 
predict the outcome of thymoma, like c-kit or HER2 
protein. It was found that c-kit is expressed by tumor 
cells in 38% of the cases with thymoma type B and the 
negative reaction is associated with better prognosis 
(Aisner et al., 2010). C-kit is expressed by 80% of the 
cases with thymic carcinoma, and together with CD5 
positive reaction, it is a useful diagnostic tool 
(Nakagawa et al., 2005). The expression of c-kit in 
thymic carcinoma and invasive thymoma deserves 
further investigations to establish a target-based 
therapy. 
Recently, a molecular analysis of 34 patients with 
thymoma showed a differential expression of the genes 
related to both metastasis and stage and there were
identified some potential candidates for the theraputic 
strategy (Badve et al., 2012). 
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Prognosis 
On one hand, the microscopic diagnosis of thymoma is 
based on the architecture of the tumor (fibrous bands, 
perivascular spaces, lost of lobulation, lack of 
differentiation between cortex and medulla), 
morphology of epithelial cells, and the presence of a 
dual cell population. On the other hand, regarding the 
prognosis, the morphologic diagnosis recognizes 
invasive and non-invasive thymoma. It is well known 
the long-term prognosis in thymoma type A and AB, 
and the malignant behavior of thymoma type C. In the 
case of thymoma type B the border between benign and 
malignant is far to be fully characterized. Actually, the 
invasion of the capsule is the only accepted 
microscopic marker of an aggressive tumor. The 
invasion of the capsule has two stages: invasion 
without penetration and invasion with penetration and 
invasion of the adipose tissue around the thymus 
(Hiroaki et al., 1999). Invasion must be checked on 
many step sections, because there were described cas s
with apparent intact capsule but containing neoplastic 
epithelial cells in capsular veins. Thus could be 
explained 15% of local recurrences in apparent 
encapsulated thymoma. 
Taken separately, anyone of these markers (excepting 
for the invasion of the capsule) may define the 
prognostic status in tumors of the thymus. This is why 
there are necessary additional studies on large seri s of 
patients with long-term follow-up. 
The overall survival of patients with thymoma for all 
stages is 67% after 5-years follow-up (stage I and II 95-
100% at 5 years and stages III and IV 33% at 3 years) 
(Schmidt-Wolf et al., 2003). Studies performed on 
large series of patients showed no differences in overall 
survival between stages I and II, and it is suggested that 
capsular invasion should not be used to define the stage 
(Asamura et al., 2004). Another critic of the actual 
stage III is given by the lack in defining the degre of 
extension. The solution could be the aggregation of 
stage I and II, and splitting the stage III based on the 
number of invaded organs. Therefore, the prognosis 
should be better reflected in survival and in accord with 
long-term overall survival. 
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